These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Josse R; Khan A; Ngui D; Shapiro M Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819 [TBL] [Abstract][Full Text] [Related]
3. Preventing osteoporosis-related fractures: an overview. Gass M; Dawson-Hughes B Am J Med; 2006 Apr; 119(4 Suppl 1):S3-S11. PubMed ID: 16563939 [TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of osteoporosis in women with breast cancer. Mincey BA; Moraghan TJ; Perez EA Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237 [TBL] [Abstract][Full Text] [Related]
5. Clinical Practice. Postmenopausal Osteoporosis. Black DM; Rosen CJ N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873 [TBL] [Abstract][Full Text] [Related]
6. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns. Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977 [TBL] [Abstract][Full Text] [Related]
7. Review of treatment modalities for postmenopausal osteoporosis. Hamdy RC; Chesnut CH; Gass ML; Holick MF; Leib ES; Lewiecki ME; Maricic M; Watts NB South Med J; 2005 Oct; 98(10):1000-14; quiz 1015-7, 1048. PubMed ID: 16295815 [TBL] [Abstract][Full Text] [Related]
8. Management of postmenopausal osteoporosis and the prevention of fractures. Gambacciani M; Levancini M Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322 [TBL] [Abstract][Full Text] [Related]
9. Management of bone health in postmenopausal women. Eastell R Horm Res; 2005; 64 Suppl 2():76-80. PubMed ID: 16286778 [TBL] [Abstract][Full Text] [Related]
10. [Therapeutic strategies for osteoporosis]. Chapurlat R; Delmas PD Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926 [TBL] [Abstract][Full Text] [Related]
11. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Wensel TM; Iranikhah MM; Wilborn TW Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
13. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Ettinger MP Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222 [TBL] [Abstract][Full Text] [Related]
16. Recognition of women at risk for fracture and intervention with fast-acting therapies. Derman R Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104 [TBL] [Abstract][Full Text] [Related]
17. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Han SL; Wan SL Int J Clin Pract; 2012 Feb; 66(2):199-209. PubMed ID: 22257045 [TBL] [Abstract][Full Text] [Related]
18. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968 [TBL] [Abstract][Full Text] [Related]
19. Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options. Pinkerton JV; Thomas S; Dalkin AC Clin Obstet Gynecol; 2013 Dec; 56(4):711-21. PubMed ID: 24100598 [TBL] [Abstract][Full Text] [Related]
20. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]